<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00909779</url>
  </required_header>
  <id_info>
    <org_study_id>091-080</org_study_id>
    <nct_id>NCT00909779</nct_id>
  </id_info>
  <brief_title>Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects</brief_title>
  <official_title>A Large Simple Safety Study of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunovion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center study to evaluate the long-term safety of arformoterol 15 mcg twice
      daily (BID) in the treatment of subjects with moderate-to-severe COPD. Study participation
      will consist of a total of 6 visits over approximately 1 year.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, double-blind, randomized, placebo-controlled, parallel-group,
      outpatient, safety study to evaluate the long-term safety of arformoterol 15 mcg twice daily
      (BID) in the treatment of subjects with moderate-to-severe COPD. The administration of
      arformoterol in subjects with moderate to severe COPD will not result in a meaningfully
      greater incidence of respiratory death and COPD exacerbation -related hospitalizations
      compared to placebo (nebulized saline and non-long-acting beta2-agonist [LABA] COPD standard
      of care treatments). This study was previously posted by Sepracor Inc. In October 2009,
      Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's
      name was changed to Sunovion Pharmaceuticals Inc.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time From Randomization to Respiratory Death or First COPD Exacerbation Related Hospitalization (Whichever Occurs First).</measure>
    <time_frame>0-12 months</time_frame>
    <description>COPD exacerbation: an increase in COPD symptoms that necessitated any change in baseline medication (bronchodilators,anti-inflammatory agents, antibiotics, supplemental oxygen therapy, etc.).Hospitalization: any inpatient admission or any emergency department visit &gt; 24 hours in duration. Hospice was considered hospitalization.COPD exacerbation related hospitalization: hospitalization that was due to 1) COPD exacerbation or 2) a COPD exacerbation preceded, or occurred concomitantly with the onset of, the event for which the subject was hospitalized.Respiratory-related death: For each death the Primary Investigator designated a 'probable cause', which was the primary condition that precipitated the terminal events that were the immediate cause of death. If a probable cause could not be ascertained, the cause of death was considered 'UNKNOWN'. Cause other than 'UNKNOWN' was categorized as either respiratory or non-respiratory. Deaths of 'UNKNOWN' cause were counted as primary events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Incidence of Protocol Defined COPD Exacerbations.</measure>
    <time_frame>0-12 months</time_frame>
    <description>A protocol-defined exacerbation of COPD was defined as an increase in respiratory symptoms (classically, increased shortness of breath, increased sputum production, and/or increased sputum purulence) that necessitates any change in baseline medication other than bronchodilators (e.g., anti-inflammatory agents, antibiotics, supplemental oxygen therapy, etc) or causes the subject to require additional medical attention (i.e., emergency room visit or hospitalization).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Incidence of All Cause Mortality</measure>
    <time_frame>0-12 months</time_frame>
    <description>Survival status at the end of the study will be determined for each subject. The proportion of subjects dead and the annual event rate will be summarized by treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Incidence of Treatment Emergent AEs</measure>
    <time_frame>0-12 months</time_frame>
    <description>TEAEs were defined as: 1) adverse events that occurred on or after the date of first dose of study medication, 2) adverse events with a missing start date and a stop date on or after the date of first does of study medication, or 3) adverse events with both a missing start and stop date.
The frequency and percentage of subjects with TEAEs were summarized. At each level of summarization, a subject was counted only once for each AE he/she experienced within that level. The percentage of subjects having had at least 1 AE at each level was calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SGRQ: Mean Change From Baseline in Total Score</measure>
    <time_frame>Baseline and on treatment at months 3, 6 and 12 (or early termination)</time_frame>
    <description>The SGRQ assessed health status and consisted of 3 component scores (Symptoms, Activity, and Impacts) as well as a total score. Items were scored in accordance with the developer's guidelines. Scores were expressed as a percentage of overall impairment, where 100 represented worst possible health status and 0 indicated best possible health status. The SGRQ was assessed pre-dose at baseline, months 3, 6 and 12 or the end of study (EOS). Visit 2 was defined as baseline. A change from baseline in the Total Score of â‰¥ 4 units is considered the minimal clinically important difference (MCID) for SGRQ.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1: Mean Change From Baseline</measure>
    <time_frame>Baseline and on treatments at months 3, 6, 9 and 12 (or early termination)</time_frame>
    <description>FEV1 was measured at Visit 1 (screening), pre- and post-albuterol administration for reversibility testing, pre-dose at baseline, months 3, 6, 9 and 12/EOS. The best FEV1 from at least 3 acceptable maneuvers was recorded. Study baseline was defined as the Visit 2 pre-dose value. If the Visit 2 pre-dose value was missing, the last FEV1 value obtained prior to first treatment was used for baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Predicted FEV1: Mean Change From Baseline</measure>
    <time_frame>Baseline and on treatments at months 3, 6, 9 and 12 (or early termination)</time_frame>
    <description>Percent predicted FEV1: measured FEV1 as a percent of the &quot;predicted values&quot; for the patients of similar characteristics (height, age, sex, and sometimes race and weight). Best FEV1 percent predicted was measured at Visit 1 (screening), pre-dose at baseline, months 3, 6, 9 and 12/EOS, as described for FEV1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC): Mean Change From Baseline</measure>
    <time_frame>Baseline and on treatment at months 3, 6, 9 and 12 (or early termination)</time_frame>
    <description>Forced Vital capacity: the volume of air that can forcibly be blown out after full inspiration. Best FVC was measured at Visit 1 (screening), pre-dose at baseline, months 3, 6, 9 and 12/EOS. The best FVC from at least 3 acceptable maneuvers was recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inspiratory Capacity (IC): Mean Change From Baseline</measure>
    <time_frame>Baseline and on treatment at months 3, 6, 9 and 12 (or early termination)</time_frame>
    <description>IC: the total amount of air that can be drawn into the lungs after normal expiration.
IC was measured pre- and post-albuterol administration at Visit 1 (screening), pre-dose at baseline, months 3, 6, 9 and 12/EOS. IC maneuvers were done in triplicate. The mean of all recorded IC values was used for each subject at each time point. Study baseline was defined as the Visit 2 pre-dose value. If the Visit 2 pre-dose value was missing, the last IC value obtained prior to first treatment dose was used for baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">841</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Arformoterol 15 mcg twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arformoterol 15 mcg twice daily by nebulization. All subjects will be dispensed albuterol HFA metered-dose inhaler (MDI) to be used as needed as rescue medication for bronchospasm and acute treatment of COPD symptoms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo twice daily</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo twice daily by nebulization. All subjects will be dispensed albuterol HFA metered-dose inhaler (MDI) to be used as needed as rescue medication for bronchospasm and acute treatment of COPD symptoms.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arformoterol</intervention_name>
    <description>Arformoterol Tartrate Inhalation Solution 15 mcg twice daily (BID) for a duration of one year</description>
    <arm_group_label>Arformoterol 15 mcg twice daily</arm_group_label>
    <other_name>Brovana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo inhalation solution, twice daily (BID) for a duration of one year.</description>
    <arm_group_label>Placebo twice daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must give written informed consent, including privacy authorization as well as
             adherence to concomitant medication withholding periods, prior to participation.

          -  Females considered not of childbearing potential must be surgically sterile (total
             hysterectomy, bilateral salpingo oophorectomy, or tubal ligation) or post-menopausal,
             which is defined as a complete cessation of menstruation for at least 1 year.

          -  Male and female subjects must be at least 40 years old at the time of consent.

          -  Subjects must have a pre-established, documented primary clinical diagnosis of
             non-asthmatic COPD or are referred for diagnosis of non-asthmatic COPD.

          -  Subjects must have a baseline FEV1 of â‰¤50% predicted volume at Visits 1 and 2
             (pre-dose).

          -  Subjects must have a FEV1 &gt;0.50 L at either Visit 1 or 2 (pre-dose).

          -  Subject's respiratory status must be clinically stable.

          -  Subjects must have a FEV1/forced vital capacity (FVC) ratio of â‰¤70% at either Visit 1
             or 2 (pre-dose).

          -  Subjects must have had at least 1 COPD exacerbation within the last year (defined as
             initiation or an increase in the dose of oral steroids or antibiotics for the
             treatment of COPD).

          -  Subjects must have a â‰¥15 pack-year smoking history and a baseline breathlessness
             severity grade of â‰¥2 (Modified Medical Research Council [MMRC] Dyspnea Scale Score) at
             Visit 2.

          -  Female subjects â‰¤65 years of age must have a negative serum pregnancy test conducted
             at Visit 1 prior to randomization. Females of childbearing potential must be using an
             acceptable method of birth control.

          -  Subjects' overall health must be sufficiently stable to complete the study
             requirements based on the screening physical examination (defined as the absence of
             any clinically relevant abnormalities), medical history, 12-lead ECG, and clinical
             laboratory values (hematology, serum chemistry and urinalysis), and vital signs (heart
             rate, respiratory rate, and blood pressure) that have been conducted within 30 days of
             Visit 2 (randomization). If any of the hematology, chemistry, or urinalysis results
             are not within the laboratory's reference range, then the subject can be included only
             if the investigator judges the deviations to be not clinically significant.

          -  Subjects must have a minimum blood pressure of 105/60 mmHg and a minimum resting pulse
             of 50 bpm at Screening Visit 1. Subjects who do not meet these criteria at Screening
             Visit 1 must meet the criteria on the first day of dosing (Day 1) in order to be
             eligible for the study. Subjects with a medical condition which causes low blood
             pressure or low heart rate, but, in the opinion of the Principal Investigator or
             designee the medical condition could resolve, may be rescreened when the condition is
             resolved.

          -  Subjects must be willing and able to complete all study questionnaires and logs
             reliably.

          -  Subjects must be willing and able to comply with study procedures and visit schedule.

          -  Subjects must have sufficient understanding of English to complete all questionnaires
             and logs.

        Exclusion Criteria:

          -  Female subjects who are pregnant or lactating.

          -  Subjects with a history of asthma, with the exception of asthma diagnosed in
             childhood.

          -  Subjects with a blood eosinophil count &gt;5% of total white blood cell count.

          -  Subjects with a febrile illness within 3 days before Screening.

          -  Subjects with a malignant neoplasm other than non melanomatous basal cell skin cancer.
             Subjects with a history of malignancy who have been cancer free for 5 years or more
             may be enrolled.

          -  Subjects who are currently using disallowed medications or will be unable to complete
             the medication washout periods. Subjects taking a prohibited concurrent medication
             which requires a washout of &gt;30 days may be rescreened when the washout of the
             prohibited concurrent medication has been met.

          -  Subjects with life threatening/unstable respiratory status, including upper or lower
             respiratory tract infection, within the previous 30 days prior to screening.

          -  Subjects who have had a change in dose or type of any medications for COPD within 2
             weeks prior to the screening visit. Subjects not on a stable dose of COPD medications
             may be rescreened after being on a stable dose for at least 14 days

          -  Subjects with a chest x ray taken â‰¤3 months prior to screening that suggests a
             diagnosis other than COPD (eg, diagnostic of pneumonia, other infection, atelectasis,
             or pneumothorax or other active/ongoing pulmonary conditions). If there is no chest x
             ray taken â‰¤3 months prior to screening, or if recent results are unavailable for
             review, a chest x ray must be performed prior to visit 2. Subjects with a medical
             condition that caused the abnormal finding, but, in the opinion of the Principal
             Investigator or designee the medical condition could resolve, may be rescreened when
             the condition is resolved

          -  Subjects with a positive urine drug test during screening.

          -  Subjects with a known history of alcohol abuse may be enrolled in the study if the
             subject's current alcohol use does not exceed more than 3 alcoholic beverages per day.

          -  Subjects whose schedule or travel prevents the completion of all required visits.

          -  Subjects who are scheduled for inpatient hospitalization or elective surgery
             (inpatient or outpatient) during the trial. Subjects may be rescreened when the
             condition is resolved.

          -  Subjects have participated in an investigational drug study and/or any COPD
             interventional trial within 30 days prior to screening or who are currently
             participating in another investigational drug study or COPD interventional trial.

          -  Subjects with a history of allergic reaction to the study medication or any components
             of the study medications.

          -  Subjects who are study site staff members or relatives of study site staff members
             directly involved in this study.

          -  Subjects with clinically significant cardiac, (Functional Class III and IV; Objective
             Class C and D by New York Heart Association [NYHA] Functional Classification),hepatic,
             renal, gastrointestinal, endocrine, metabolic, neurologic, or psychiatric disorder
             that may interfere with successful completion of this protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Jefferson Clinic</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>25233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alabama Clinical Therapeutic, LLC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Achieve Clinical Research</name>
      <address>
        <city>Brimingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jasper Summit Research, LLC</name>
      <address>
        <city>Jasper</city>
        <state>Alabama</state>
        <zip>35501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chest Critical Care Consultants</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Research Medical Group</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrated Research Group</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality Control Research Inc.</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sockolov and Sockolov APC</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centers for Clinical Trials of Sacremento</name>
      <address>
        <city>Sacremento</city>
        <state>California</state>
        <zip>95823</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of HealthCare Assessment, Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Clinical Research</name>
      <address>
        <city>Chiefland</city>
        <state>Florida</state>
        <zip>32626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa Bay Medical Research Inc.</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida, Inc.</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avail Clinical Research</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Lung Clinic, P.A.</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DCT</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Canton</city>
        <state>Georgia</state>
        <zip>30114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Regional Research Group</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Pharmaceutical Research</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellstar Marietta Pulmonary Medicine</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Regional Research Group</name>
      <address>
        <city>Rincon</city>
        <state>Georgia</state>
        <zip>31326</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisphere Medical Research Center</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentucky Lung Clinic</name>
      <address>
        <city>Hazard</city>
        <state>Kentucky</state>
        <zip>41701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bendel Medical Research Center, LLC</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinSite LLC</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute Inc.</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Chest Consultants</name>
      <address>
        <city>St. Charles</city>
        <state>Missouri</state>
        <zip>63301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.A.R.E. Clinical Research</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Clinical Research</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Delaware Valley Clinical Research</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <zip>08003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Pulmonary and Clinical Care Associates, PC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENT &amp; Allergy Associates</name>
      <address>
        <city>Newburgh</city>
        <state>New York</state>
        <zip>12550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AAIR Research Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Health Research Inc.</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Medical Research</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DayStar Clinical Research, Inc.</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44313</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bernstein Clinical Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute of Southern Oregon, PC</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Associates Research Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcuri Clinical Research, LLC</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19142</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biomedical Research Alliance at Hypertension and Nephrology</name>
      <address>
        <city>Pawtucket</city>
        <state>Rhode Island</state>
        <zip>02860</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Medical Research</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lowcountry Lung &amp; Critical Care, PA</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neem Research Group, Inc.</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gaffney Pharmaceutical Research</name>
      <address>
        <city>Gaffney</city>
        <state>South Carolina</state>
        <zip>29340</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Pharmaceutical Research</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Upstate Pharmaceutical Research</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mountain View Clinical Research, Inc.</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S. Carolina Pharmaceutical Research</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CU Pharmaceutical Research</name>
      <address>
        <city>Union</city>
        <state>South Carolina</state>
        <zip>29379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Associates</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Volunteer Research Group</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DCT</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine, Clinical Studies Unit, Ben Taub General Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VAMC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kingwood Research Institute, LLC</name>
      <address>
        <city>Kingwood</city>
        <state>Texas</state>
        <zip>77339</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physician PrimeCare Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostics Research Group</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DCT</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77878</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SouthEast Research Institute</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Clinical Resources, Inc.</name>
      <address>
        <city>Provo</city>
        <state>Utah</state>
        <zip>84604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Clinical Trials LLC</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlottesville Medical Research Inc.</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manassas Clinical Research Center</name>
      <address>
        <city>Manassas</city>
        <state>Virginia</state>
        <zip>20110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dominion Medical Associates</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary Associates of Richmond Inc.</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary Associates of Richmond, Inc.</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary Consultants, PLLC</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Albania</country>
  </removed_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2009</study_first_submitted>
  <study_first_submitted_qc>May 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2009</study_first_posted>
  <results_first_submitted>June 21, 2013</results_first_submitted>
  <results_first_submitted_qc>September 12, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 11, 2013</results_first_posted>
  <last_update_submitted>September 12, 2013</last_update_submitted>
  <last_update_submitted_qc>September 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic obstructive pulmonary disease (COPD)</keyword>
  <keyword>respiratory</keyword>
  <keyword>long-acting beta agonist (LABA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo Twice Daily</title>
          <description>Placebo twice daily by nebulization. All subjects will be dispensed albuterol HFA metered-dose inhaler (MDI) to be used as needed as rescue medication for bronchospasm and acute treatment of COPD symptoms.</description>
        </group>
        <group group_id="P2">
          <title>Arformoterol 15 Mcg Twice Daily</title>
          <description>Arformoterol 15 mcg twice daily by nebulization. All subjects will be dispensed albuterol HFA metered-dose inhaler (MDI) to be used as needed as rescue medication for bronchospasm and acute treatment of COPD symptoms.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="421"/>
                <participants group_id="P2" count="420"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="211">All subjects but 47 were followed for 12 months/until death (whichever was earlier).</participants>
                <participants group_id="P2" count="255">All subjects but 42 were followed for 12 months/until death (whichever was earlier).</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="210"/>
                <participants group_id="P2" count="165"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="116"/>
                <participants group_id="P2" count="80"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site Ceasing Operation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Medical Monitor Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized in error</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Comparator: Placebo Twice Daily</title>
          <description>Placebo twice daily by nebulization. All subjects will be dispensed albuterol HFA metered-dose inhaler (MDI) to be used as needed as rescue medication for bronchospasm and acute treatment of COPD symptoms.</description>
        </group>
        <group group_id="B2">
          <title>Experimental: Arformoterol 15 Mcg Twice Daily</title>
          <description>Arformoterol 15 mcg twice daily by nebulization. All subjects will be dispensed albuterol HFA metered-dose inhaler (MDI) to be used as needed as rescue medication for bronchospasm and acute treatment of COPD symptoms.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="421"/>
            <count group_id="B2" value="420"/>
            <count group_id="B3" value="841"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="222"/>
                    <measurement group_id="B2" value="204"/>
                    <measurement group_id="B3" value="426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="199"/>
                    <measurement group_id="B2" value="216"/>
                    <measurement group_id="B3" value="415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.3" spread="9.5"/>
                    <measurement group_id="B2" value="64.2" spread="9.3"/>
                    <measurement group_id="B3" value="63.8" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="178"/>
                    <measurement group_id="B2" value="183"/>
                    <measurement group_id="B3" value="361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="243"/>
                    <measurement group_id="B2" value="236"/>
                    <measurement group_id="B3" value="479"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Undifferentiated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="402"/>
                    <measurement group_id="B2" value="411"/>
                    <measurement group_id="B3" value="813"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="374"/>
                    <measurement group_id="B2" value="372"/>
                    <measurement group_id="B3" value="746"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="421"/>
                    <measurement group_id="B2" value="420"/>
                    <measurement group_id="B3" value="841"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of COPD exacerbations in last year</title>
          <description>The average number of COPD exacerbations during the previous year</description>
          <units>Number of occurrences</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.8" spread="1.1"/>
                    <measurement group_id="B2" value="1.0" spread="1.4"/>
                    <measurement group_id="B3" value="0.9" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FEV1</title>
          <description>FEV1: Forced expiratory volume in one second. FEV1 was measured at Visit 1 (screening), pre- and post-albuterol administration for reversibility testing, pre-dose at Visits 2 through 5, and at Visit 6/EOS. The best FEV1 from at least 3 acceptable maneuvers was recorded. Study baseline was defined as the Visit 2 pre-dose value. If the Visit 2 pre-dose value was missing, the last FEV1 value obtained prior to first treatment was used for baseline.</description>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.178" spread="0.487"/>
                    <measurement group_id="B2" value="1.176" spread="0.482"/>
                    <measurement group_id="B3" value="1.177" spread="0.485"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percent predicted FEV1 (%)</title>
          <description>Best FEV1 percent predicted was measured at Visit 1 (screening), pre-dose at Visits 2 through 5, and at Visit 6/EOS, as described for FEV1.</description>
          <units>Percentage (%)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.4" spread="13.9"/>
                    <measurement group_id="B2" value="39.7" spread="13.2"/>
                    <measurement group_id="B3" value="39.5" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline smoking status</title>
          <description>Smoking status was recorded at each visit. At baseline, a subject was only defined as a former smoker if they had given up smoking at least 6 calendar months prior to the Visit 1 (screening) date based on the smoking cessation date. Otherwise, they were classified as a current smoker.</description>
          <units>Current</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Current</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="218"/>
                    <measurement group_id="B2" value="214"/>
                    <measurement group_id="B3" value="432"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Former</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="203"/>
                    <measurement group_id="B2" value="206"/>
                    <measurement group_id="B3" value="409"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of pack-years smoked</title>
          <description>Number of pack-years smoked was defined as the number of cigarette packs smoked per day times the number of years smoked.</description>
          <units>Pack-years</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>â‰¥ 15 - &lt; 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41" spread="9.7"/>
                    <measurement group_id="B2" value="40" spread="9.5"/>
                    <measurement group_id="B3" value="81" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>â‰¥ 25 - &lt; 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36" spread="8.6"/>
                    <measurement group_id="B2" value="29" spread="6.9"/>
                    <measurement group_id="B3" value="65" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>â‰¥ 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="344" spread="81.7"/>
                    <measurement group_id="B2" value="351" spread="83.6"/>
                    <measurement group_id="B3" value="695" spread="82.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Oral/Inhaled Corticosteroid Use</title>
          <description>Oral or inhaled corticosteroid use</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="202" spread="48.0"/>
                    <measurement group_id="B2" value="202" spread="48.1"/>
                    <measurement group_id="B3" value="404" spread="48.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="219" spread="52.0"/>
                    <measurement group_id="B2" value="218" spread="51.9"/>
                    <measurement group_id="B3" value="437" spread="52.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Oxygen Therapy Use</title>
          <description>Oxygen therapy use at baseline</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="330" spread="78.4"/>
                    <measurement group_id="B2" value="334" spread="79.5"/>
                    <measurement group_id="B3" value="664" spread="79.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91" spread="21.6"/>
                    <measurement group_id="B2" value="86" spread="20.5"/>
                    <measurement group_id="B3" value="177" spread="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time From Randomization to Respiratory Death or First COPD Exacerbation Related Hospitalization (Whichever Occurs First).</title>
        <description>COPD exacerbation: an increase in COPD symptoms that necessitated any change in baseline medication (bronchodilators,anti-inflammatory agents, antibiotics, supplemental oxygen therapy, etc.).Hospitalization: any inpatient admission or any emergency department visit &gt; 24 hours in duration. Hospice was considered hospitalization.COPD exacerbation related hospitalization: hospitalization that was due to 1) COPD exacerbation or 2) a COPD exacerbation preceded, or occurred concomitantly with the onset of, the event for which the subject was hospitalized.Respiratory-related death: For each death the Primary Investigator designated a â€˜probable causeâ€™, which was the primary condition that precipitated the terminal events that were the immediate cause of death. If a probable cause could not be ascertained, the cause of death was considered â€˜UNKNOWNâ€™. Cause other than â€˜UNKNOWNâ€™ was categorized as either respiratory or non-respiratory. Deaths of â€˜UNKNOWNâ€™ cause were counted as primary events.</description>
        <time_frame>0-12 months</time_frame>
        <population>Intent-to-treat population: subjects who were randomized to treatment and received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: Arformoterol 15 Mcg Twice Daily</title>
            <description>Arformoterol 15 mcg twice daily by nebulization. All subjects will be dispensed albuterol HFA metered-dose inhaler (MDI) to be used as needed as rescue medication for bronchospasm and acute treatment of COPD symptoms.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Randomization to Respiratory Death or First COPD Exacerbation Related Hospitalization (Whichever Occurs First).</title>
          <description>COPD exacerbation: an increase in COPD symptoms that necessitated any change in baseline medication (bronchodilators,anti-inflammatory agents, antibiotics, supplemental oxygen therapy, etc.).Hospitalization: any inpatient admission or any emergency department visit &gt; 24 hours in duration. Hospice was considered hospitalization.COPD exacerbation related hospitalization: hospitalization that was due to 1) COPD exacerbation or 2) a COPD exacerbation preceded, or occurred concomitantly with the onset of, the event for which the subject was hospitalized.Respiratory-related death: For each death the Primary Investigator designated a â€˜probable causeâ€™, which was the primary condition that precipitated the terminal events that were the immediate cause of death. If a probable cause could not be ascertained, the cause of death was considered â€˜UNKNOWNâ€™. Cause other than â€˜UNKNOWNâ€™ was categorized as either respiratory or non-respiratory. Deaths of â€˜UNKNOWNâ€™ cause were counted as primary events.</description>
          <population>Intent-to-treat population: subjects who were randomized to treatment and received at least 1 dose of study medication.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="420"/>
                <count group_id="O2" value="421"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Subjects with Primary Event</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155.0" spread="91.2" lower_limit="0.425" upper_limit="0.864"/>
                    <measurement group_id="O2" value="171.7" spread="98.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is: There is 40% or higher excess risk of the primary events in the arformoterol group relative to placebo (a constant hazard ratio of 1.4).
The primary analysis was a Cox proportional hazards regression model, with treatment group, baseline smoking status, sex, age, BMI, and baseline FEV1 as covariates. The hazard ratio and 90% two-sided confidence interval for the hazard ratio (adjusted for the interim analysis) comparing arformoterol to placebo were estimated.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The study was powered under a one-sided alternative hypothesis, in which arformoterol is superior to placebo, with a hazard ratio of 0.80 or less. To achieve 80% power, it was necessary to observe 86 total events for the primary endpoint adjusted for interim analysis. Assuming an annual event proportion of 17.3% in the placebo group and 30% lost to follow-up, we anticipated to randomize approximately 900 subjects (450 per arm).
The non-inferiority margin for the hazard ratio is 1.4.</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.606</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.425</ci_lower_limit>
            <ci_upper_limit>0.864</ci_upper_limit>
            <estimate_desc>Hazard ratio was calculated as arformoterol vs. placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Incidence of Protocol Defined COPD Exacerbations.</title>
        <description>A protocol-defined exacerbation of COPD was defined as an increase in respiratory symptoms (classically, increased shortness of breath, increased sputum production, and/or increased sputum purulence) that necessitates any change in baseline medication other than bronchodilators (e.g., anti-inflammatory agents, antibiotics, supplemental oxygen therapy, etc) or causes the subject to require additional medical attention (i.e., emergency room visit or hospitalization).</description>
        <time_frame>0-12 months</time_frame>
        <population>Intent-to-treat population: subjects who were randomized to treatment and received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Comparator: Placebo Twice Daily</title>
            <description>Placebo twice daily by nebulization. All subjects will be dispensed albuterol HFA metered-dose inhaler (MDI) to be used as needed as rescue medication for bronchospasm and acute treatent of COPD symptoms.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: Arformoterol 15 Mcg Twice Daily</title>
            <description>Arformoterol 15 mcg twice daily by nebulization. All subjects will be dispensed albuterol HFA metered-dose inhaler (MDI) to be used as needed as rescue medication for bronchospasm and acute treatment of COPD symptoms.</description>
          </group>
        </group_list>
        <measure>
          <title>The Incidence of Protocol Defined COPD Exacerbations.</title>
          <description>A protocol-defined exacerbation of COPD was defined as an increase in respiratory symptoms (classically, increased shortness of breath, increased sputum production, and/or increased sputum purulence) that necessitates any change in baseline medication other than bronchodilators (e.g., anti-inflammatory agents, antibiotics, supplemental oxygen therapy, etc) or causes the subject to require additional medical attention (i.e., emergency room visit or hospitalization).</description>
          <population>Intent-to-treat population: subjects who were randomized to treatment and received at least 1 dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="421"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132"/>
                    <measurement group_id="O2" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 COPD event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 COPD events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 or more COPD events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Incidence of All Cause Mortality</title>
        <description>Survival status at the end of the study will be determined for each subject. The proportion of subjects dead and the annual event rate will be summarized by treatment.</description>
        <time_frame>0-12 months</time_frame>
        <population>Intent-to-treat population: subjects who were randomized to treatment and received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Comparator: Placebo Twice Daily</title>
            <description>Placebo twice daily by nebulization. All subjects will be dispensed albuterol HFA metered-dose inhaler (MDI) to be used as needed as rescue medication for bronchospasm and acute treatent of COPD symptoms.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: Arformoterol 15 Mcg Twice Daily</title>
            <description>Arformoterol 15 mcg twice daily by nebulization. All subjects will be dispensed albuterol HFA metered-dose inhaler (MDI) to be used as needed as rescue medication for bronchospasm and acute treatment of COPD symptoms.</description>
          </group>
        </group_list>
        <measure>
          <title>The Incidence of All Cause Mortality</title>
          <description>Survival status at the end of the study will be determined for each subject. The proportion of subjects dead and the annual event rate will be summarized by treatment.</description>
          <population>Intent-to-treat population: subjects who were randomized to treatment and received at least 1 dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="421"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Incidence of Treatment Emergent AEs</title>
        <description>TEAEs were defined as: 1) adverse events that occurred on or after the date of first dose of study medication, 2) adverse events with a missing start date and a stop date on or after the date of first does of study medication, or 3) adverse events with both a missing start and stop date.
The frequency and percentage of subjects with TEAEs were summarized. At each level of summarization, a subject was counted only once for each AE he/she experienced within that level. The percentage of subjects having had at least 1 AE at each level was calculated.</description>
        <time_frame>0-12 months</time_frame>
        <population>Intent-to-treat population: subjects who were randomized to treatment and received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Comparator: Placebo Twice Daily</title>
            <description>Placebo twice daily by nebulization. All subjects will be dispensed albuterol HFA metered-dose inhaler (MDI) to be used as needed as rescue medication for bronchospasm and acute treatent of COPD symptoms.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: Arformoterol 15 Mcg Twice Daily</title>
            <description>Arformoterol 15 mcg twice daily by nebulization. All subjects will be dispensed albuterol HFA metered-dose inhaler (MDI) to be used as needed as rescue medication for bronchospasm and acute treatment of COPD symptoms.</description>
          </group>
        </group_list>
        <measure>
          <title>The Incidence of Treatment Emergent AEs</title>
          <description>TEAEs were defined as: 1) adverse events that occurred on or after the date of first dose of study medication, 2) adverse events with a missing start date and a stop date on or after the date of first does of study medication, or 3) adverse events with both a missing start and stop date.
The frequency and percentage of subjects with TEAEs were summarized. At each level of summarization, a subject was counted only once for each AE he/she experienced within that level. The percentage of subjects having had at least 1 AE at each level was calculated.</description>
          <population>Intent-to-treat population: subjects who were randomized to treatment and received at least 1 dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="421"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="287"/>
                    <measurement group_id="O2" value="306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SGRQ: Mean Change From Baseline in Total Score</title>
        <description>The SGRQ assessed health status and consisted of 3 component scores (Symptoms, Activity, and Impacts) as well as a total score. Items were scored in accordance with the developerâ€™s guidelines. Scores were expressed as a percentage of overall impairment, where 100 represented worst possible health status and 0 indicated best possible health status. The SGRQ was assessed pre-dose at baseline, months 3, 6 and 12 or the end of study (EOS). Visit 2 was defined as baseline. A change from baseline in the Total Score of â‰¥ 4 units is considered the minimal clinically important difference (MCID) for SGRQ.</description>
        <time_frame>Baseline and on treatment at months 3, 6 and 12 (or early termination)</time_frame>
        <population>Intent-to-treat population: subjects who were randomized to treatment and received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Comparator: Placebo Twice Daily</title>
            <description>Placebo twice daily by nebulization. All subjects will be dispensed albuterol HFA metered-dose inhaler (MDI) to be used as needed as rescue medication for bronchospasm and acute treatent of COPD symptoms.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: Arformoterol 15 Mcg Twice Daily</title>
            <description>Arformoterol 15 mcg twice daily by nebulization. All subjects will be dispensed albuterol HFA metered-dose inhaler (MDI) to be used as needed as rescue medication for bronchospasm and acute treatment of COPD symptoms.</description>
          </group>
        </group_list>
        <measure>
          <title>SGRQ: Mean Change From Baseline in Total Score</title>
          <description>The SGRQ assessed health status and consisted of 3 component scores (Symptoms, Activity, and Impacts) as well as a total score. Items were scored in accordance with the developerâ€™s guidelines. Scores were expressed as a percentage of overall impairment, where 100 represented worst possible health status and 0 indicated best possible health status. The SGRQ was assessed pre-dose at baseline, months 3, 6 and 12 or the end of study (EOS). Visit 2 was defined as baseline. A change from baseline in the Total Score of â‰¥ 4 units is considered the minimal clinically important difference (MCID) for SGRQ.</description>
          <population>Intent-to-treat population: subjects who were randomized to treatment and received at least 1 dose of study medication.</population>
          <units>Score</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="421"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3 (n=276,308)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.544" spread="0.609"/>
                    <measurement group_id="O2" value="-3.876" spread="0.575"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=233,287)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.855" spread="0.746"/>
                    <measurement group_id="O2" value="-4.054" spread="0.679"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=199,236)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.673" spread="0.800"/>
                    <measurement group_id="O2" value="-4.796" spread="0.735"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS (n=375,379)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.587" spread="0.616"/>
                    <measurement group_id="O2" value="-3.231" spread="0.613"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1: Mean Change From Baseline</title>
        <description>FEV1 was measured at Visit 1 (screening), pre- and post-albuterol administration for reversibility testing, pre-dose at baseline, months 3, 6, 9 and 12/EOS. The best FEV1 from at least 3 acceptable maneuvers was recorded. Study baseline was defined as the Visit 2 pre-dose value. If the Visit 2 pre-dose value was missing, the last FEV1 value obtained prior to first treatment was used for baseline.</description>
        <time_frame>Baseline and on treatments at months 3, 6, 9 and 12 (or early termination)</time_frame>
        <population>Intent-to-treat population: subjects who were randomized to treatment and received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Comparator: Placebo Twice Daily</title>
            <description>Placebo twice daily by nebulization. All subjects will be dispensed albuterol HFA metered-dose inhaler (MDI) to be used as needed as rescue medication for bronchospasm and acute treatent of COPD symptoms.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: Arformoterol 15 Mcg Twice Daily</title>
            <description>Arformoterol 15 mcg twice daily by nebulization. All subjects will be dispensed albuterol HFA metered-dose inhaler (MDI) to be used as needed as rescue medication for bronchospasm and acute treatment of COPD symptoms.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1: Mean Change From Baseline</title>
          <description>FEV1 was measured at Visit 1 (screening), pre- and post-albuterol administration for reversibility testing, pre-dose at baseline, months 3, 6, 9 and 12/EOS. The best FEV1 from at least 3 acceptable maneuvers was recorded. Study baseline was defined as the Visit 2 pre-dose value. If the Visit 2 pre-dose value was missing, the last FEV1 value obtained prior to first treatment was used for baseline.</description>
          <population>Intent-to-treat population: subjects who were randomized to treatment and received at least 1 dose of study medication.</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="421"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3 (n=289,331)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.027" spread="0.018"/>
                    <measurement group_id="O2" value="0.093" spread="0.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=248,300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.036" spread="0.023"/>
                    <measurement group_id="O2" value="0.090" spread="0.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (n=223,268)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.048" spread="0.019"/>
                    <measurement group_id="O2" value="0.092" spread="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=206,253)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.020" spread="0.020"/>
                    <measurement group_id="O2" value="0.059" spread="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS (n=380,391)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.047" spread="0.016"/>
                    <measurement group_id="O2" value="0.072" spread="0.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Predicted FEV1: Mean Change From Baseline</title>
        <description>Percent predicted FEV1: measured FEV1 as a percent of the &quot;predicted values&quot; for the patients of similar characteristics (height, age, sex, and sometimes race and weight). Best FEV1 percent predicted was measured at Visit 1 (screening), pre-dose at baseline, months 3, 6, 9 and 12/EOS, as described for FEV1.</description>
        <time_frame>Baseline and on treatments at months 3, 6, 9 and 12 (or early termination)</time_frame>
        <population>Intent-to-treat population: subjects who were randomized to treatment and received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Comparator: Placebo Twice Daily</title>
            <description>Placebo twice daily by nebulization. All subjects will be dispensed albuterol HFA metered-dose inhaler (MDI) to be used as needed as rescue medication for bronchospasm and acute treatent of COPD symptoms.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: Arformoterol 15 Mcg Twice Daily</title>
            <description>Arformoterol 15 mcg twice daily by nebulization. All subjects will be dispensed albuterol HFA metered-dose inhaler (MDI) to be used as needed as rescue medication for bronchospasm and acute treatment of COPD symptoms.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Predicted FEV1: Mean Change From Baseline</title>
          <description>Percent predicted FEV1: measured FEV1 as a percent of the &quot;predicted values&quot; for the patients of similar characteristics (height, age, sex, and sometimes race and weight). Best FEV1 percent predicted was measured at Visit 1 (screening), pre-dose at baseline, months 3, 6, 9 and 12/EOS, as described for FEV1.</description>
          <population>Intent-to-treat population: subjects who were randomized to treatment and received at least 1 dose of study medication.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="421"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3 (n=289,331)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.410" spread="0.533"/>
                    <measurement group_id="O2" value="3.480" spread="0.498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=248,300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.768" spread="0.648"/>
                    <measurement group_id="O2" value="3.460" spread="0.594"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (n=223,268)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.606" spread="0.626"/>
                    <measurement group_id="O2" value="3.651" spread="0.576"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=206,252)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.678" spread="0.642"/>
                    <measurement group_id="O2" value="2.662" spread="0.586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS (n=380,391)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.156" spread="0.493"/>
                    <measurement group_id="O2" value="2.936" spread="0.486"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC): Mean Change From Baseline</title>
        <description>Forced Vital capacity: the volume of air that can forcibly be blown out after full inspiration. Best FVC was measured at Visit 1 (screening), pre-dose at baseline, months 3, 6, 9 and 12/EOS. The best FVC from at least 3 acceptable maneuvers was recorded.</description>
        <time_frame>Baseline and on treatment at months 3, 6, 9 and 12 (or early termination)</time_frame>
        <population>Intent-to-treat population: subjects who were randomized to treatment and received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Comparator: Placebo Twice Daily</title>
            <description>Placebo twice daily by nebulization. All subjects will be dispensed albuterol HFA metered-dose inhaler (MDI) to be used as needed as rescue medication for bronchospasm and acute treatent of COPD symptoms.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: Arformoterol 15 Mcg Twice Daily</title>
            <description>Arformoterol 15 mcg twice daily by nebulization. All subjects will be dispensed albuterol HFA metered-dose inhaler (MDI) to be used as needed as rescue medication for bronchospasm and acute treatment of COPD symptoms.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC): Mean Change From Baseline</title>
          <description>Forced Vital capacity: the volume of air that can forcibly be blown out after full inspiration. Best FVC was measured at Visit 1 (screening), pre-dose at baseline, months 3, 6, 9 and 12/EOS. The best FVC from at least 3 acceptable maneuvers was recorded.</description>
          <population>Intent-to-treat population: subjects who were randomized to treatment and received at least 1 dose of study medication.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="421"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3 (n=289,331)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.039" spread="0.024"/>
                    <measurement group_id="O2" value="0.139" spread="0.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=248,300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.056" spread="0.031"/>
                    <measurement group_id="O2" value="0.120" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (n=223,268)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.049" spread="0.029"/>
                    <measurement group_id="O2" value="0.139" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=206,253)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.040" spread="0.029"/>
                    <measurement group_id="O2" value="0.088" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS (n=380,391)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.056" spread="0.022"/>
                    <measurement group_id="O2" value="0.102" spread="0.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inspiratory Capacity (IC): Mean Change From Baseline</title>
        <description>IC: the total amount of air that can be drawn into the lungs after normal expiration.
IC was measured pre- and post-albuterol administration at Visit 1 (screening), pre-dose at baseline, months 3, 6, 9 and 12/EOS. IC maneuvers were done in triplicate. The mean of all recorded IC values was used for each subject at each time point. Study baseline was defined as the Visit 2 pre-dose value. If the Visit 2 pre-dose value was missing, the last IC value obtained prior to first treatment dose was used for baseline.</description>
        <time_frame>Baseline and on treatment at months 3, 6, 9 and 12 (or early termination)</time_frame>
        <population>Intent-to-treat population: subjects who were randomized to treatment and received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Comparator: Placebo Twice Daily</title>
            <description>Placebo twice daily by nebulization. All subjects will be dispensed albuterol HFA metered-dose inhaler (MDI) to be used as needed as rescue medication for bronchospasm and acute treatent of COPD symptoms.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: Arformoterol 15 Mcg Twice Daily</title>
            <description>Arformoterol 15 mcg twice daily by nebulization. All subjects will be dispensed albuterol HFA metered-dose inhaler (MDI) to be used as needed as rescue medication for bronchospasm and acute treatment of COPD symptoms.</description>
          </group>
        </group_list>
        <measure>
          <title>Inspiratory Capacity (IC): Mean Change From Baseline</title>
          <description>IC: the total amount of air that can be drawn into the lungs after normal expiration.
IC was measured pre- and post-albuterol administration at Visit 1 (screening), pre-dose at baseline, months 3, 6, 9 and 12/EOS. IC maneuvers were done in triplicate. The mean of all recorded IC values was used for each subject at each time point. Study baseline was defined as the Visit 2 pre-dose value. If the Visit 2 pre-dose value was missing, the last IC value obtained prior to first treatment dose was used for baseline.</description>
          <population>Intent-to-treat population: subjects who were randomized to treatment and received at least 1 dose of study medication.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="421"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3 (n=284,320)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.030" spread="0.023"/>
                    <measurement group_id="O2" value="0.054" spread="0.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=243,298)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.011" spread="0.026"/>
                    <measurement group_id="O2" value="0.067" spread="0.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (n=218,258)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.046" spread="0.029"/>
                    <measurement group_id="O2" value="0.096" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=199,246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004" spread="0.029"/>
                    <measurement group_id="O2" value="0.035" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS (n=374,384)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.031" spread="0.022"/>
                    <measurement group_id="O2" value="0.058" spread="0.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo Comparator: Placebo Twice Daily</title>
          <description>Placebo twice daily by nebulization. All subjects will be dispensed albuterol HFA metered-dose inhaler (MDI) to be used as needed as rescue medication for bronchospasm and acute treatment of COPD symptoms.</description>
        </group>
        <group group_id="E2">
          <title>Experimental: Arformoterol 15 Mcg Twice Daily</title>
          <description>Arformoterol 15 mcg twice daily by nebulization. All subjects will be dispensed albuterol HFA metered-dose inhaler (MDI) to be used as needed as rescue medication for bronchospasm and acute treatment of COPD symptoms.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="421"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Bundle branch block right</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="421"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Corpulmonale</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Retinal artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Barrett's oesophagus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="421"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Gallbladder perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="421"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Gastritis fungal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Gastroenteritis bacteria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Osteomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Osteomyelitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Peridiverticular abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="14" subjects_at_risk="421"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Open wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Throat cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Carotid artery aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Carotid artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Urethral obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="76" subjects_affected="55" subjects_at_risk="421"/>
                <counts group_id="E2" events="44" subjects_affected="35" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="421"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Iliac artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="180" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="174" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="36" subjects_affected="28" subjects_at_risk="421"/>
                <counts group_id="E2" events="58" subjects_affected="43" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="49" subjects_affected="33" subjects_at_risk="421"/>
                <counts group_id="E2" events="50" subjects_affected="38" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="29" subjects_affected="22" subjects_at_risk="421"/>
                <counts group_id="E2" events="27" subjects_affected="19" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="26" subjects_affected="22" subjects_at_risk="421"/>
                <counts group_id="E2" events="28" subjects_affected="22" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="39" subjects_affected="21" subjects_at_risk="421"/>
                <counts group_id="E2" events="53" subjects_affected="35" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="122" subjects_affected="83" subjects_at_risk="421"/>
                <counts group_id="E2" events="115" subjects_affected="75" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="46" subjects_affected="30" subjects_at_risk="421"/>
                <counts group_id="E2" events="27" subjects_affected="24" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Although LABAs other than study medication were discontinued, other medications were not controlled for. A large number of subjects discontinued after a primary event and their eventual outcomes are unknown.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Respiratory Medical Director</name_or_title>
      <organization>Sunovion</organization>
      <phone>1-866-503-6351</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

